Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 5/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21273264 | 0.90 | SMO (0.42) | SMOMAOAMAOBMAPTNPC1 | |
| SCHEMBL21282151 | 0.90 | PKM (0.36) | SMOMAOAMAOBF2RL3MIF | |
| SCHEMBL21273250 | 0.86 | MAPT (0.48) | F2RL3MIFMAPTPDE10A | |
| SCHEMBL21273258 | 0.85 | SMO (0.36) | SMOMAOAMAOBF2RL3MAPT | |
| SCHEMBL21282154 | 0.79 | NPC1 (0.45) | SMOMAOAMAOBMAPTNPC1 | |
| SCHEMBL21282152 | 0.76 | MAPT (0.47) | MIFMAPTPKMALDH1A1PDE10A | |
| SCHEMBL21273256 | 0.75 | S1PR1 (0.48) | MAPTNPC1PKMRAB9AHSP90AA1 | |
| SCHEMBL21282155 | 0.75 | PKM (0.35) | SMOMAOAMAOBF2RL3MAPT | |
| SCHEMBL21282191 | 0.66 | SMO (0.42) | SMOMAPTNPC1PKMRAB9A | |
| SCHEMBL21282172 | 0.66 | NPC1 (0.61) | MAPTNPC1PKMRAB9AHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012394-B2 | Alpha-synuclein ligands | WASHINGTON UNIVERSITY (US) | 2024-06-18 | — | — | US | disclosed |
| US-20190256492-A1 | ALPHA-SYNUCLEIN LIGANDS | WASHINGTON UNIVERSITY (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256492-A1 | ALPHA-SYNUCLEIN LIGANDS | SNCA, PARK7, LRRK2 | SMO 3104/4885MAOA 1234/4885MAOB 912/4885 |
| US-12012394-B2 | Alpha-synuclein ligands | SNCA, PARK7, LRRK2 | SMO 3104/4885MAOA 1234/4885MAOB 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.